Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting
Presentation Details:
Title: | Suprachoroidal CLS-TA and IOP: Results from the Phase 3 PEACHTREE Clinical Trial |
Author: | Steven Yeh, M.D., Associate Professor, Emory Eye Center |
Date/Time: | Sunday, October 13th / 3:15 p.m.; also available as an ePoster |
Poster #: | PO522 |
Title: | Suprachoroidal Delivery for Ocular Gene Therapy: Nonclinical Experiments Evaluating Nonviral DNA Nanoparticles |
Author: | Christine N. Kay, M.D., Vitreo Retinal Associates; Affiliate Assistant Professor in the Department of Ophthalmology, University of South Florida |
Date/Time: | Sunday, October 13th / 5:00 p.m.; also available as an ePoster |
Poster #: | PO395 |
Title: | A Subgroup Analysis of Subjects Diagnosed With Anterior Uveitis From the Phase 3 PEACHTREE Clinical Trial |
Author: | Ashleigh L. Levison, M.D., Colorado Retina Associates |
Date/Time: | Monday, October 14th / 8:30 a.m. |
Paper #: | PA031 |
Title: | Disorganization of the Retinal Inner Layers as a Biomarker: Results of the TYBEE Phase 2 in DME |
Author: | Michael S. Ip, M.D., Doheny Eye Institute, David Geffen School of Medicine at University of California Los Angeles, CA |
Date/Time: | ePoster |
Poster #: | PO485 |
About
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the potential to bring XIPERE to market for uveitis patients, opportunities for expanding Clearside’s internal pipeline, and the potential benefits of XIPERE and the SCS injection platform. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended
Investor and Media Contacts:
ir@clearsidebio.com
(678) 430-8206
Source:
Source: Clearside Biomedical, Inc.